HPV vaccine: An overview of immune response, clinical protection, and new approaches for the future

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Mariani, Luciano ^a   Venuti, Aldo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

L2E6E7 VACCINE; PEPTIDE L2; POLYPEPTIDE; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18;

ANTIBODY PRODUCTION; CELLULAR IMMUNITY; COTTONTAIL RABBIT PAPILLOMAVIRUS; DRUG COST; DRUG EFFICACY; GENOTYPE; HOST RESISTANCE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNIZATION; INFECTION PREVENTION; INNATE IMMUNITY; LONG TERM CARE; NONHUMAN; PAPILLOMAVIRUS INFECTION; REVIEW; UTERINE CERVIX CANCER; VACCINE PRODUCTION; VERRUCA VULGARIS; VIRUS CELL INTERACTION; ALPHAPAPILLOMAVIRUS; CROSS REACTION; FEMALE; IMMUNOLOGY; UTERINE CERVIX TUMOR;

ALPHAPAPILLOMAVIRUS; CROSS REACTIONS; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 77958470634     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-105     Document Type: Review

References (74)

1. Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003, 31:14-9.
2. Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, Sparrow J, Lorincz A, . Survey of HPV in Ontario Women Group Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 2003, 168:421-5. 143547, 12591782, Survey of HPV in Ontario Women Group.
3. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Wacholder S, Tarone R, Burk RD. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005, 191(11):1808-16. 10.1086/428779, 15871112.
4. Castellsagué X, Achim S, Andreas M, Kaufmann B, Bosch FX. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol 2009, 115(3 Suppl):S15-23. 10.1016/j.ygyno.2009.09.021, 19819540.
5. Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 2007, 25:4324-4333. 10.1016/j.vaccine.2007.02.069, 17445955.
6. David MP, van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, van Damme P. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol 2009, 115(3 Suppl):S1-6. Epub 2009 Feb 12, 10.1016/j.ygyno.2009.01.011, 19217149.
7. Ong CK, Chan SY, Campo MS, Fujinaga K, Mavromara-Nazos P, Labropoulou V, Pfister H, Tay SK, ter Meulen J, Villa LL. Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J Virol 1993, 67:6424-31. 238077, 8411344.
8. Xi LF, Kiviat NB, Hildesheim A, Galloway DA, Wheeler CM, Ho J, Koutsky LA. Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst 2006, 98:1045-52. 10.1093/jnci/djj297, 16882941.
9. Bernard H, Itzel CE, Dunn ST. Genome variation of human papillomavirus types: Phylogenetic and medical Implications. Int J Cancer 2006, 118:1071-1076. 10.1002/ijc.21655, 16331617.
10. Frazer I. Correlating immunity with protection for HPV infection. Int J Infectious Dis 2007, 11(Supplement 2):S10-S16.
11. Einstein M, Schiller JT, Viscidi RP, Strickler H, Coursaget P, Tan T, Halsey N, Jenkins D. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009, 9:347-56. 10.1016/S1473-3099(09)70108-2, 19467474.
12. Koshiol JE, Schroeder JC, Jamieson DJ, Marshall SW, Duerr A, Heilig CM, Shah KV, Klein RS, Cu-Uvin S, Schuman P, Celentano D, Smith JS. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer 2006, 119:1623-9. 10.1002/ijc.22015, 16646070.
13. Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 2001, 8:209-20. 96039, 11238198.
14. Coleman N, Birley HD, Renton AM, Hanna NF, Ryait BK, Byrne M, Taylor-Robinson D, Stanley MA. Immunological events in regressing genital warts. Am J Clin Pathol 1994, 102:768-774.
15. Nicholls PK, Moore PF, Anderson DM, Moore RA, Parry NR, Gough GW, Stanley MA. Regression of canine oral papillomas is associated with infiltration of CD4{thorn} and CD8{thorn} lymphocytes. Virology 2001, 283:31-39. 10.1006/viro.2000.0789, 11312659.
16. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000, 181:1911-9. 10.1086/315498, 10837170.
17. Fausch SC, Da Silva DM, Rudolf MP, Kast WM. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 2002, 169:3242-9.
18. Fausch SC, Da Silva DM, Kast WM. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res 2003, 63:3478-82.
19. Wang SS, Schiffman M, Herrero R, Carreon J, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Clayman B, Burk RD, Viscidi RP. Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica. Br J Cancer 2004, 91:1269-1274. 10.1038/sj.bjc.6602088, 2409899, 15292929.
20. Ferris D, Garland S, . for the Quadrivalent HPV Vaccine Investigators Evaluation of quadrivalent hpv 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with prior vaccine hpv type infection. 2008, The 13th International Congress on Infectious Diseases Kuala Lumpur, Malaysia, for the Quadrivalent HPV Vaccine Investigators.
21. WHO position paper, No. 15. 2009, 84:118-132.
22. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006, 24:5571-83. 10.1016/j.vaccine.2006.04.068, 16753240.
23. Harper D, Gall S, Naud P, Quint W, Dubin G, Jenkins D. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long-term follow up through 6.4 years in women vaccinated with Cervarix™ (GSK's HPV 16/18 AS04 candidate vaccine). Society of Gynecologic Oncologists 39th Annual Meeting on Women's Cancer. Tampa; 2008. Mar 9-12
24. The Future II Study Group Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007, 369:1861-68. 10.1016/S0140-6736(07)60852-6, 17544766, The Future II Study Group.
25. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin GG, . for the HPV PATRICIA study group Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-70. 10.1016/S0140-6736(07)60946-5, 17602732, for the HPV PATRICIA study group.
26. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow S, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner S, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki F, Schwarz T, Poppe W, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, . for the HPV PATRICIA Study Group Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study inyoung women. Lancet 2009, 374:301-14. 10.1016/S0140-6736(09)61248-4, 19586656, for the HPV PATRICIA Study Group.
27. Schwarz T, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature. Gynecol Oncol 2008, 110:S1-S10. 10.1016/j.ygyno.2008.05.036, 18653222.
28. David J. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008, 110:S18-S25. 10.1016/j.ygyno.2008.06.027, 18653221.
29. Joura E, Kjaer S, Wheeler C, Sigurdssond K, Iversen OE, Hernandez-Avila M, Perez G, Brown D, Koutsky L, Hseon Tay E, García P, Ault K, Garland S, Leodolter S, Olsson SE, Tango G, Ferris D, Paavonen J, Lehtinen M, Steben M, Bosch X, Dillner J, Kurman R, Majewski S, Munoz N, Myers E, Villa LL, Taddeo F, Roberts C, Tadesse A, Bryan J, Lupinacci L, Giacoletti K, Lu S, Vuocolo S, Hesley T, Haupt R, Barr EH. PV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008, 26:6844-6851. 10.1016/j.vaccine.2008.09.073, 18930097.
30. Van Herck K, Van Damme P. Prevention of hepatitis A by Havrix: a review. Expert Rev Vaccines 2005, 4(4):459-71. 10.1586/14760584.4.4.459, 16117704.
31. Stanley M, Moore RA, Nicholls PK, Santos EB, Thomsen L, Parry N, Walcott S, Gough G. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPVin beagle dogs. Vaccine 2001, 19:2783-92. 10.1016/S0264-410X(00)00533-8, 11282188.
32. Margaret S. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008, 109:S15-S21. 10.1016/j.ygyno.2008.02.003, 18474288.
33. GlaxoSmithKline Vaccine HPV-007 Study Group Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-85. 10.1016/S0140-6736(09)61567-1, 19962185, GlaxoSmithKline Vaccine HPV-007 Study Group.
34. Paolini F, Venuti A. Other good news from prophylactic HPV vaccines: long-term duration of immunity. Womens Health (Lond Engl) 2010, 6:361-3.
35. European Consensus Group on Hepatitis B Immunity Are booster immunizations needed for lifelong hepatitis B immunity. Lancet 2002, 355:561-5. European Consensus Group on Hepatitis B Immunity.
36. Ault KA. Long-term efficacy of human papillomavirus vaccination. Gynecol Oncol 2007, 107:S27-S30. 10.1016/j.ygyno.2007.07.078, 17938016.
37. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin M, Gary D, Wettendorff MA. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24:5937-49. 10.1016/j.vaccine.2006.06.005, 16828940.
38. Einstein M, Baron M, Levin M, Chatterjee A, Edwards R, Zepp F, Carletti I, Dessy F, Trofa A, Schuind A, . Dubin G on behalf of the HPV-010 Study Group Comparison of the immunogenicity and safety of CervarixTM and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Human Vaccines 2009, 5(10):1-15. Dubin G on behalf of the HPV-010 Study Group.
39. WHO Guidelines to assure the quality, safety and efficacy of recombinant HPV virus-like particle vaccines. 2006, WHO., http://screening.iarc.fr/doc/WHO_vaccine_guidelines_2006.pdf
40. Olsson SE, Villa LL, Costa R, Petta C, Andrade R, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Lehtinen M, Paavonen J, Tamms G, Giacoletti K, Lupinacci L, Esser M, Vuocolo S, Saah A, Barr E. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007, 25:4931-4939. 10.1016/j.vaccine.2007.03.049, 17499406.
41. Lin H, Ma YY, Moh JS, Ou YC, Shen SY, Changchien CC. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan. Gynecol Oncol 2006, 101:40-45. 10.1016/j.ygyno.2005.09.028, 16256180.
42. Miyashita M, Agdamag DM, Sasagawa T, Matsushita L, Salud LM, Salud CO, Saikawa K, Leano PS, Pagcaliwagan T, Acuna J, Ishizaki A, Kageyama S, Ichimura H. High-risk HPV types in lesions of the uterine cervix of female commercial sex workers in the Philippines. J Med Virol 2009, 81:545-551. 10.1002/jmv.21416, 19152419.
43. Shin HR, Franceschi S, Vaccarella S, Roh JW, Ju YH, Oh JK, Kong HJ, Rha SH, Jung SI, Kim JI, Jung KY, Van Doorn LJ, Quint W. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 2004, 190:468-476. 10.1086/421279, 15243918.
44. Roden R, Wu TC. How will HPV vaccines affect cervical cancer?. Nat Rev Cancer 2006, 6:753-763. 10.1038/nrc1973, 16990853.
45. Brown D, Kjaer S, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler C, Perez G, Koutsky L, Hseon Tay E, Garcia P, Ault K, Garland S, Leodolter S, Olsson SE, Tang G, Ferris D, Paavonen J, Steben M, Bosch FX, Dillner J, Joura E, Kurman R, Majewski S, Muñoz N, Myers E, Villa LL, Taddeo F, Roberts C, Tadesse A, Bryan J, Lupinacci L, Giacoletti K, Sings H, James M, Hesley T, Bar E. The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years. JID 2009, 199:926-35. 10.1086/597307, 19236279.
46. Wheeler C, Kjaer S, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown D, Koutsky L, Hseon Tay E, García P, Ault K, Garland S, Leodolter S, Olsson SE, Tang G, Ferris G, Paavonen J, Steben M, Bosch FX, Dillner J, Joura E, Kurman R, Majewski R, Muñoz N, Myers ER, Villa LL, Taddeo F, Roberts C, Tadesse A, Bryan J, Lupinacci L, Giacoletti K, James M, Vuocolo S, Hesley T, Bar E. The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years. JID 2009, 199:936-44. 10.1086/597309, 19236277.
47. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008, 110:S18-S25. 10.1016/j.ygyno.2008.06.027, 18653221.
48. Campo MS, Grindlay GJ, O'Neil BW, Chandrachud LM, McGarvie GM, Jarrett WF. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 1993, 74:945-953. 10.1099/0022-1317-74-6-945, 8389809.
49. Christensen ND, Kreider JW, Kan NC, DiAngelo SL. The open reading frame L2 of cottontail rabbit papillomavirus contains antibodyinducing neutralizing epitopes. Virology 1991, 181:572-579. 10.1016/0042-6822(91)90890-N, 1707567.
50. Embers ME, Budgeon LR, Pickel M, Christensen ND. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol 2002, 76:9798-9805. 10.1128/JVI.76.19.9798-9805.2002, 136504, 12208958.
51. Gaukroger JM, Chandrachud LM, O'Neil BW, Grindlay GJ, Knowles G, Campo MS. Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. J Gen Virol 1996, 77:1577-1583. 10.1099/0022-1317-77-7-1577, 8758002.
52. McGarvie GM, Chandrachud LM, Gaukroger J, Grindlay GJ, O'Neil BW, Baird JW, Wagner ER, Jarrett WFH, Campo MS. Vaccination of cattle with L2 protein prevents BPV-4 infection. Papillomavirus immunology 1994, 283-290. Plenum Publishing Corporation, New York, NY, Stanley MA.
53. Lin YL, Borenstein LA, Selvakumar R, Ahmed R, Wettstein FO. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology 1992, 187:612-619. 10.1016/0042-6822(92)90463-Y, 1312271.
54. Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, Christensen ND, Roden RBS. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 2007, 81(21):11585-92. Epub 2007 Aug 22, 10.1128/JVI.01577-07, 2168774, 17715230.
55. Pastrana DV, Gambhira R, Buck CB, Pang Y-YS, Thompson CD, Culp TD, Christensen ND, Lowy DR, Schiller JT, Roden RBS. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005, 337:365-372. 10.1016/j.virol.2005.04.011, 15885736.
56. Gambhira R, Gravitt P, Bossis I, Stern P, Viscidi RP, Roden R. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res 2006, 66:11120-11124. 10.1158/0008-5472.CAN-06-2560, 17145854.
57. Liu WJ, Gissmann L, Sun Y, Kanjanahaluethai A, Muller M, Doorbar J, Zhou J. Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions. Virology 1997, 227:474-483. 10.1006/viro.1996.8348, 9018146.
58. Day P, Gambhira R, Roden R, Lowy D, Schiller J. Mechanisms of human papillomavirus type 16 neutralization by L2 cross-neutralizing and L1 type-specific antibodies. J Virol 2008, 82:4638-4646. 10.1128/JVI.00143-08, 2293042, 18305047.
59. Day P, Lowy D, Schiller J. Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids. J Virol 2008, 82:12565-12568. 10.1128/JVI.01631-08, 2593329, 18829767.
60. Slupetzky K, Gambhira R, Culp T, Shafti-Keramat S, Schellenbacher C, Christensen N, Roden R, Kirnbauer R. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 2007, 25:2001-2010. 10.1016/j.vaccine.2006.11.049, 17239496.
61. Rubio I, Bolchi A, Moretto N, Canali E, Gissmann L, Tommasino M, Muller M, Ottonello S. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20-38) peptide displayed on bacterial thioredoxin. Vaccine 27:1949-1956. 10.1016/j.vaccine.2009.01.102, 19368776.
62. Alphs H, Gambhira R, Karanam B, Roberts J, Jagu S, Schiller J, Zeng W, Jackson D, Roden R. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 2008, 105:5850-5855. 10.1073/pnas.0800868105, 2299222, 18413606.
63. Jagu S, Karanam B, Gambhira R, Chivukula S, Chaganti R, Lowy D, Schiller J, Roden R. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009, 101:782-792. 10.1093/jnci/djp106, 2689872, 19470949.
64. Yuan H, Estes P, Chen Y, Newsome Y, Olcese V, Garcea R, Schlegel R. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol 2001, 75:7848-7853. 10.1128/JVI.75.17.7848-7853.2001, 115027, 11483728.
65. Baud D, Ponci F, Bobst M, De Grandi P, Nardelli-Haefliger D. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol 2004, 78:12901-12909. 10.1128/JVI.78.23.12901-12909.2004, 524992, 15542642.
66. Fraillery D, Baud D, Pang S, Schiller J, Bobst M, Zosso N, Ponci F, Nardelli-Haefliger D. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol 2007, 14:1285-1295. 10.1128/CVI.00164-07, 2168124, 17687110.
67. Franconi R, Venuti A. HPV Vaccines in Plants: an appetising solution to Control Infection and Associated Cancers. Papillomavirus research: from Natural History to Vaccines and Beyond 2006, 357-372. Norfolk, U.K.: Caister Academic Press, Saveria Campo M.
68. Rybicki EP. Plant-produced vaccines: promise and reality. Drug Discov Today 2009, 14(1-2):16-24. Epub 2008 Nov 18, 10.1016/j.drudis.2008.10.002, 18983932.
69. Biemelt S, Sonnewald U, Galmbacher P, Willmitzer L, Müller M. Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol 2003, 77:9211-9220. 10.1128/JVI.77.17.9211-9220.2003, 187377, 12915537.
70. Varsani A, Williamson AL, Rose RC, Jaffer M, Rybicki EP. Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi. Arch Virol 2003, 148:1771-1786. 10.1007/s00705-003-0119-4, 14505089.
71. Warzecha H, Mason HS, Lane C, Tryggvesson A, Rybicki E, Williamson AL, Clements JD, Rose RC. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol 2003, 77:8702-8711. 10.1128/JVI.77.16.8702-8711.2003, 167207, 12885889.
72. Fernandez-San Millan A, Ortigosa SM, Hervás-Stubbs S, Corral-Martínez P, Seguí-Simarro JM, Gaétan J, Coursaget P, Veramendi J. Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol J 2008, 6:427-441. 10.1111/j.1467-7652.2008.00338.x, 18422886.
73. Paz De la Rosa G, Monroy-García A, Mora-García Mde L, Peña CG, Hernández-Montes J, Weiss-Steider B, Gómez-Lim MA. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice. Virol J 2009, 6:6-2. 10.1186/1743-422X-6-6, 2637244, 19149901.
74. Mariani L. HPV-vaccine and screening programs: the new era of global prevention. J Prev Med Hyg 2009, 50(2):90-5.